Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078369314> ?p ?o ?g. }
Showing items 1 to 89 of
89
with 100 items per page.
- W2078369314 endingPage "1804" @default.
- W2078369314 startingPage "1796" @default.
- W2078369314 abstract "In a recent multicentre, randomised, controlled, open-label study ( 1 Rougier P. Van Cutsem E. Bajetta E. et al. Phase III trial of irinotecan versus infusional fluorouracil in patients with metastatic colorectal cancer after fluorouracil failure. Lancet. 1998; 352: 1407-1412 Abstract Full Text Full Text PDF PubMed Scopus (992) Google Scholar ), irinotecan significantly increased survival without any deterioration in quality of life compared with best-estimated infusional 5-fluorouracil (5-FU) therapy in the setting of second-line treatment for metastatic colorectal cancer. The aim of the cost-effectiveness analysis reported here was to compare the economic implications, from a U.K. perspective, of replacing 5-FU therapy [either as a single agent (Lokich regimen, B2) or in combination with folinic acid (de Gramont regimen, B1, or AIO regimen, B3)] with irinotecan as second-line therapy for metastatic colorectal cancer. Resource utilisation data collected prospectively during the study, supplemented by both a questionnaire to investigators and local expert clinical opinion, were used as a basis for estimating cumulative drug dosage, chemotherapy administration and treatment of complications. Drug acquisition costs were derived from the British National Formulary ( 15 British National Formulary. Number 35, March 1998. Google Scholar ), and unit costs for clinical consultation and services were derived from relevant 1996/1997 cost databases. Although cumulative drug acquisition costs per patient were higher with irinotecan than with infusional 5-FU therapy, these were at least partially offset by lower cumulative costs per patient associated with administration of therapy and treatment of complications in the irinotecan arm than in the 5-FU arm. Based on the incremental costs per life year gained (LYG), irinotecan was considered to be cost-effective by commonly accepted criteria compared with either the B1 or B2 regimens. Irinotecan was cost-saving compared with the B3 regimen (that is significant survival gain and a reduction in costs). Thus, not only is there strong evidence for the use of irinotecan as standard second-line therapy in metastatic colorectal cancer, but the results of this prospective economic evaluation have shown that irinotecan also represents good value for money in this clinical setting." @default.
- W2078369314 created "2016-06-24" @default.
- W2078369314 creator A5027160662 @default.
- W2078369314 creator A5040330310 @default.
- W2078369314 creator A5051506824 @default.
- W2078369314 creator A5090645179 @default.
- W2078369314 date "1999-12-01" @default.
- W2078369314 modified "2023-10-08" @default.
- W2078369314 title "Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU" @default.
- W2078369314 cites W1811602282 @default.
- W2078369314 cites W1832060645 @default.
- W2078369314 cites W1859092351 @default.
- W2078369314 cites W1902766545 @default.
- W2078369314 cites W1941365207 @default.
- W2078369314 cites W1969825132 @default.
- W2078369314 cites W1987073889 @default.
- W2078369314 cites W2003679194 @default.
- W2078369314 cites W2006824814 @default.
- W2078369314 cites W2011476349 @default.
- W2078369314 cites W2039652696 @default.
- W2078369314 cites W2056131235 @default.
- W2078369314 cites W2096122707 @default.
- W2078369314 cites W2100198463 @default.
- W2078369314 cites W2157908657 @default.
- W2078369314 doi "https://doi.org/10.1016/s0959-8049(99)00186-0" @default.
- W2078369314 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10673994" @default.
- W2078369314 hasPublicationYear "1999" @default.
- W2078369314 type Work @default.
- W2078369314 sameAs 2078369314 @default.
- W2078369314 citedByCount "36" @default.
- W2078369314 countsByYear W20783693142012 @default.
- W2078369314 countsByYear W20783693142013 @default.
- W2078369314 countsByYear W20783693142015 @default.
- W2078369314 countsByYear W20783693142016 @default.
- W2078369314 crossrefType "journal-article" @default.
- W2078369314 hasAuthorship W2078369314A5027160662 @default.
- W2078369314 hasAuthorship W2078369314A5040330310 @default.
- W2078369314 hasAuthorship W2078369314A5051506824 @default.
- W2078369314 hasAuthorship W2078369314A5090645179 @default.
- W2078369314 hasConcept C100406419 @default.
- W2078369314 hasConcept C121608353 @default.
- W2078369314 hasConcept C126322002 @default.
- W2078369314 hasConcept C141071460 @default.
- W2078369314 hasConcept C143998085 @default.
- W2078369314 hasConcept C2776694085 @default.
- W2078369314 hasConcept C2778336483 @default.
- W2078369314 hasConcept C2779804826 @default.
- W2078369314 hasConcept C2780259306 @default.
- W2078369314 hasConcept C2780456651 @default.
- W2078369314 hasConcept C2781413609 @default.
- W2078369314 hasConcept C526805850 @default.
- W2078369314 hasConcept C71924100 @default.
- W2078369314 hasConcept C98274493 @default.
- W2078369314 hasConceptScore W2078369314C100406419 @default.
- W2078369314 hasConceptScore W2078369314C121608353 @default.
- W2078369314 hasConceptScore W2078369314C126322002 @default.
- W2078369314 hasConceptScore W2078369314C141071460 @default.
- W2078369314 hasConceptScore W2078369314C143998085 @default.
- W2078369314 hasConceptScore W2078369314C2776694085 @default.
- W2078369314 hasConceptScore W2078369314C2778336483 @default.
- W2078369314 hasConceptScore W2078369314C2779804826 @default.
- W2078369314 hasConceptScore W2078369314C2780259306 @default.
- W2078369314 hasConceptScore W2078369314C2780456651 @default.
- W2078369314 hasConceptScore W2078369314C2781413609 @default.
- W2078369314 hasConceptScore W2078369314C526805850 @default.
- W2078369314 hasConceptScore W2078369314C71924100 @default.
- W2078369314 hasConceptScore W2078369314C98274493 @default.
- W2078369314 hasIssue "13" @default.
- W2078369314 hasLocation W20783693141 @default.
- W2078369314 hasLocation W20783693142 @default.
- W2078369314 hasOpenAccess W2078369314 @default.
- W2078369314 hasPrimaryLocation W20783693141 @default.
- W2078369314 hasRelatedWork W1987707107 @default.
- W2078369314 hasRelatedWork W2003872607 @default.
- W2078369314 hasRelatedWork W2010991676 @default.
- W2078369314 hasRelatedWork W2034983765 @default.
- W2078369314 hasRelatedWork W2088650389 @default.
- W2078369314 hasRelatedWork W2129298161 @default.
- W2078369314 hasRelatedWork W2136055188 @default.
- W2078369314 hasRelatedWork W2418999078 @default.
- W2078369314 hasRelatedWork W2599610220 @default.
- W2078369314 hasRelatedWork W3010640843 @default.
- W2078369314 hasVolume "35" @default.
- W2078369314 isParatext "false" @default.
- W2078369314 isRetracted "false" @default.
- W2078369314 magId "2078369314" @default.
- W2078369314 workType "article" @default.